Press Releases
Celator Pharmaceuticals completes enrollment in a second phase 2...
Celator Pharmaceuticals announced that it has completed enrollment in a phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus intensive salvage...
Press Releases
Eurand Presents Data on ZENPEP(R) Without Proton Pump Inhibitors...
Eurand Pharmaceuticals, Inc., a subsidiary of global specialty pharmaceutical company Eurand N.V. announced additional data from a post-hoc analysis of a Phase III clinical trial...
Press Releases
Cephalon Announces FDA Approval of Risk Evaluation and Mitigation...
Cephalon, Inc. (Nasdaq: CEPH) today announced that Risk Evaluation and Mitigation Strategies (REMS) for its medications NUVIGIL(R) (armodafinil) Tablets and PROVIGIL(R) (modafinil) Tablets ...
Press Releases
FDA approves Herceptin for HER2-positive metastatic stomach cancer
Roche announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil ) for...
Press Releases
Amylin, Lilly and Alkermes Announce Receipt of Complete Response...
Amylin Pharmaceuticals, Inc. Eli Lilly and Company and Alkermes, Inc.announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding...
Press Releases
Endress+Hauser Announces Collaboration with SAP as a Core Partner...
SAP Research is the global technology research unit of SAP. The group significantly contributes to SAP's product portfolio and extends its leading position...
Press Releases
NeurogesX to Pursue Expanded U.S Label for Qutenza(R) 8%...
NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced plans to pursue a U.S. label expansion for Qutenza(R)...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.